Survey 37 - Clinical Insight MappingMCI Registration NumberFULL NAME (As in your Pancard)EmailPhone/MobileCityStateSpecialityBank DetailsAccount Holder NameA/c NumberIFSC CodeUpload Cancelled Cheque (Max Size - 2 MB)Choose File Pancard NumberUpload Pancard Details (Max Size - 2 MB)Choose File Clinical Insight Mapping: LRTI & Cefpodoxime Proxetil1. When managing a suspected Lower Respiratory Tract Infection (LRTI) in an outpatient setting, which clinical sign most frequently triggers your decision to initiate empirical antibiotic therapy? Productive cough for >3 days Presence of high-grade fever with purulent sputum Auscultatory findings (e.g., rales or rhonchi) Patient demand for rapid symptom relief2. What is your primary rationale for selecting Cefpodoxime Proxetil (200mg) over Amoxicillin-Clavulanate for Community-Acquired Pneumonia (CAP)? Superior coverage against atypical pathogens Better gastrointestinal tolerability profile Lower cost to the patient Extended half-life allowing for once-daily dosing3. In patients with Acute Exacerbation of Chronic Bronchitis (AECB), how do you rank the importance of S.pneumoniae vs. H.influenzae coverage when choosing Cefpodoxime? Priority is given to Gram-positive coverage (S.pneumoniae) Priority is given to Gram-negative coverage (H.influenzae & M.catarrhalis) Both are weighted equally in my selection process Coverage is secondary to the drug’s lung tissue penetration levels4. How does the "prodrug" nature of Cefpodoxime Proxetil influence your prescribing confidence regarding bioavailability? I prefer it because it minimizes direct gastric mucosal irritation I am concerned about absorption variability based on food intake It has no impact on my clinical decision-making I perceive it as having faster onset of action than non-prodrugs5. For which patient profile do you consider Cefpodoxime 200mg BD (twice daily) as the first-line "Switch Therapy" after initial IV Ceftriaxone? Geriatric patients with multiple comorbidities Patients showing clinical stabilization after 48-72 hours of IV therapy Pediatric patients with mild bronchitis Only in cases of confirmed penicillin allergy6. Which "Value-Added" attribute of Cefpodoxime Proxetil do you find most compelling for patient compliance in LRTIs? The BID (twice daily) dosing schedule Small tablet size/ease of swallowing Minimal dietary restrictions Low incidence of antibiotic-associated diarrhea7. When treating LRTIs, how often do you prescribe Cefpodoxime 200mg in combination with a Macrolide (e.g., Azithromycin)? Frequently (to cover atypical pathogens) Only if the patient fails to respond to monotherapy after 48 hours Rarely (I prefer monotherapy to reduce resistance) Never (I perceive a high risk of drug-drug interactions)8. In your practice, what is the typical duration of Cefpodoxime Proxetil (200mg) therapy for an uncomplicated LRTI? 3 days 5 days 7–10 days 14 days9. What is the most significant barrier to prescribing Cefpodoxime Proxetil for your LRTI patients? Perceived lack of efficacy against Beta−lactamase producing strains Price sensitivity of the patient Availability of newer-generation Macrolides Concerns regarding the development of ESBL resistance10. How do you rate the importance of "Tissue Penetration" (specifically Epithelial Lining Fluid levels) when selecting Cefpodoxime for lung infections? Extremely Important Moderately Important Slightly Important Not Important I have read and agree to the Terms and Conditions .Submit Form